SCD

Summary

SCD (stearoyl-CoA desaturase, HGNC:10571) is a protein-coding gene on chromosome 10q24.31, encoding Stearoyl-CoA desaturase (O00767). Stearoyl-CoA desaturase that utilizes O(2) and electrons from reduced cytochrome b5 to introduce the first double bond into saturated fatty acyl-CoA substrates. It is a selective cancer dependency (DepMap: 67.2% of cell lines).

This gene encodes an enzyme involved in fatty acid biosynthesis, primarily the synthesis of oleic acid. The protein belongs to the fatty acid desaturase family and is an integral membrane protein located in the endoplasmic reticulum. Transcripts of approximately 3.9 and 5.2 kb, differing only by alternative polyadenlyation signals, have been detected. A gene encoding a similar enzyme is located on chromosome 4 and a pseudogene of this gene is located on chromosome 17.

Source: NCBI Gene 6319 — RefSeq curated summary.

At a glance

• Gene–disease (curated): adrenoleukodystrophy (Limited, GenCC)
• Clinical variants (ClinVar): 33 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 67.2% of screened cell lines
• MANE Select transcript: NM_005063

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10571
Approved symbol	SCD
Name	stearoyl-CoA desaturase
Location	10q24.31
Locus type	gene with protein product
Status	Approved
Aliases	FADS5, SCD1
Ensembl gene	ENSG00000099194
Ensembl biotype	protein_coding
OMIM	604031
Entrez	6319

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 6 protein_coding

ENST00000370355, ENST00000884319, ENST00000884320, ENST00000884321, ENST00000884322, ENST00000911677

RefSeq mRNA: 1 — MANE Select: NM_005063 NM_005063

CCDS: CCDS7493

Canonical transcript exons

ENST00000370355 — 6 exons

Exon	Start	End
ENSE00000720696	100352366	100352496
ENSE00000720697	100354427	100354632
ENSE00000720699	100356532	100356764
ENSE00000811324	100348064	100348346
ENSE00001452458	100360734	100364826
ENSE00001452460	100347233	100347531

Expression profiles

Bgee: expression breadth ubiquitous, 289 present calls, max score 99.89.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 245.4468 / max 21596.1616, expressed in 1780 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
106524	120.0416	1231
106520	78.4562	1736
106517	23.8323	1704
106518	8.6489	1586
106519	5.6227	1407
106523	2.6720	858
106525	2.5774	755
106529	2.2930	742
106522	0.6569	367
106516	0.5342	271

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
inferior vagus X ganglion	UBERON:0005363	99.89	gold quality
subthalamic nucleus	UBERON:0001906	99.86	gold quality
superior vestibular nucleus	UBERON:0007227	99.85	gold quality
medulla oblongata	UBERON:0001896	99.83	gold quality
substantia nigra pars reticulata	UBERON:0001966	99.81	gold quality
substantia nigra pars compacta	UBERON:0001965	99.76	gold quality
lateral globus pallidus	UBERON:0002476	99.76	gold quality
pons	UBERON:0000988	99.74	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	99.69	gold quality
ventral tegmental area	UBERON:0002691	99.68	gold quality
globus pallidus	UBERON:0001875	99.66	gold quality
inferior olivary complex	UBERON:0002127	99.65	gold quality
endothelial cell	CL:0000115	99.64	gold quality
medial globus pallidus	UBERON:0002477	99.64	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	99.60	gold quality
midbrain	UBERON:0001891	99.51	gold quality
substantia nigra	UBERON:0002038	99.48	gold quality
Brodmann (1909) area 46	UBERON:0006483	99.46	gold quality
cranial nerve II	UBERON:0000941	99.45	gold quality
lateral nuclear group of thalamus	UBERON:0002736	99.45	gold quality
trigeminal ganglion	UBERON:0001675	99.37	gold quality
spinal cord	UBERON:0002240	99.29	gold quality
ventricular zone	UBERON:0003053	99.26	gold quality
amygdala	UBERON:0001876	99.25	gold quality
hypothalamus	UBERON:0001898	99.24	gold quality
Ammon’s horn	UBERON:0001954	99.20	gold quality
parietal lobe	UBERON:0001872	99.19	gold quality
corpus callosum	UBERON:0002336	99.17	gold quality
postcentral gyrus	UBERON:0002581	99.15	gold quality
embryo	UBERON:0000922	99.08	gold quality

Single-cell (SCXA)

Detected in 13 experiment(s), a significant marker in 11.

Experiment	Marker?	Max mean expression
E-MTAB-8495	yes	2432.11
E-GEOD-86618	yes	757.95
E-MTAB-8221	yes	660.91
E-HCAD-1	yes	92.32
E-HCAD-35	yes	73.55
E-HCAD-25	yes	53.77
E-ANND-3	yes	27.99
E-GEOD-93593	yes	18.41
E-GEOD-130148	yes	14.68
E-GEOD-84465	yes	13.34
E-GEOD-83139	yes	8.09
E-MTAB-6075	no	955.57
E-MTAB-9689	no	689.53

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

177 targeting SCD, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 67.2% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• Inhibition of stearoyl-CoA desaturase activity by the cis-9,trans-11 isomer and the trans-10,cis-12 isomer of conjugated linoleic acid in human breast cancer cells. (PMID:12061775)
• stearoyl-CoA desaturase influence on plasma triglycerides in hypertriglyceridemia (PMID:12401889)
• Of genes identified in the liver whose expression is modulated by leptin, stearoyl-CoA desaturase-1 ranks at the top of the list, according to this review. (PMID:14683458)
• relationship between triglyceride levels and the ratio of plasma oleic acid to stearic acid (the 18:1/18:0 ratio), a plasma marker of SCD activity, and n-3 PUFAs in 411 Japanese, 418 Korean, and 251 Mongolian adults (PMID:14967817)
• increased palmitate and stearate desaturation by stearoyl-CoA desaturase was associated with the destabilization of ABCA1 by saturated fatty acids palmitate and stearate (PMID:14967823)
• loss of SCD expression is a frequent event in prostate adenocarcinoma (PMID:15609334)
• The identification and characterization of SCD2, and its relationship to human SCD1 and mouse SCD2, are reported. (PMID:15610069)
• No evidence that SCD sequence variation influences diabetes susceptibility or related traits. (PMID:15662557)
• Results suggest that stearoyl-CoA desaturase levels are associated with the events of neoplastic cell transformation and programmed cell death. (PMID:15708362)
• by globally regulating lipid metabolism, stearoyl-CoA desaturase activity modulates cell proliferation and survival and shows the role of endogenously synthesized monounsaturated fatty acids in sustaining the neoplastic phenotype of transformed cells (PMID:15851470)
• SCD activity index after rosiglitazone in PPARgamma mutation supports a pivotal role of PPARgamma function in SCD regulation. (PMID:15855323)
• the lipogenic gene, stearoyl-CoA desaturase 1 (SCD1), is robustly up-regulated in skeletal muscle from extremely obese humans Elevated expression of SCD1 in skeletal muscle contributes to abnormal lipid metabolism and progression of obesity. (PMID:16213227)
• SCD1 was degraded constitutively irrespective of the cellular levels of unsaturated fatty acids, which strictly regulate SCD1 gene expression. (PMID:16723740)
• study demonstrated that the gene expression of COX-2 and stearoyl-coenzyme A desaturase diminished in the chronic phase of Graves’ophthalmopathy in parallel with a decrease in clinical activity score (PMID:17614770)
• Genetic variations in the SCD1 gene are associated with body fat distribution and insulin sensitivity. (PMID:17636091)
• The results indicate that when the supply of FA to HL60 cells is limited, the intracellular content of n-3 and n-6 FA decreases and this leads to upregulation of the desaturases, D9D is doubled. (PMID:17852835)
• Results show that elevated SCD activity within adipose tissue is closely coupled to the development of insulin resistance. (PMID:18030445)
• High hepatic SCD1 activity may regulate fat accumulation in the liver and possibly protects from insulin resistance in obesity. (PMID:18286258)
• Fatty acid desaturation index (a marker of SCD1 activity) is a highly heritable trait that is associated with the dyslipidemia observed in familial combined hyperlipidemia. (PMID:18340007)
• age-related reduction in polyunsaturated fatty acid composition was inversely correlated with SCD expression and activity resulting in elevations in monounsaturated fatty acid composition (PMID:18499418)
• Changed expression of downstream PPARgamma targets after stearoyl CoA desaturase (SCD) knockdown suggests that PPARgamma up-regulation of SCD leads to increased lipogenesis and potentiation of adiponectin signaling. (PMID:18697866)
• SCD1 activity regulates Akt activation in human lung adenocarcinoma cells (PMID:18813799)
• Dyslipidemia and atherosclerosis induced by chronic intermittent hypoxia are attenuated by deficiency of stearoyl coenzyme A desaturase. (PMID:18832746)
• Data show that human fatty liver is characterized by increases in hepatic stearoyl-CoA desaturase (SCD1) and lipogenic activities. (PMID:18952834)
• decrease in lipid accumulation in apoE-transfected cells was associated with a strong downregulation of PPARs gamma1 and gamma2 and stearoyl-CoA desaturase 1 (PMID:19130493)
• associations of Delta 9 with adiposity and plasma lipids in healthy female adolescents support the concept derived from rodent models that Delta 9 activity is independently reflective of higher body mass index and higher circulatory triglyceride levels (PMID:19154947)
• SCD1 inducibility by palmitate is an individual characteristic that modulates lipid storage, palmitate-induced inflammation, endoplasmic reticulum stress, and insulin resistance. (PMID:19478146)
• data suggest that cancer cells require active SCD1 to control the rate of glucose-mediated lipogenesis, and that when SCD1 activity is impaired cells downregulate SFA synthesis via AMPK-mediated inactivation of acetyl-CoA carboxylase (PMID:19710915)
• Exogenous palmitate up-regulated de novo lipogenesis concomitantly with SCD and elongation (PMID:20032470)
• SNPs in the fatty acid desaturase gene are associated with higher blood essential fatty acids and perinatal depression. (PMID:20395685)
• potential role in disease onset and development (Review) (PMID:20565855)
• lower expression in dendritic cells compared to macrophages (PMID:20579763)
• This study demonstrates that the foreign SCD1 gene was expressed with high efficiency and induced elevated c9t11-CLA, t10c12-CLA, and n-7 fatty acid levels in mammalian cells. (PMID:20599700)
• Oleic acid, the main product of SCD1 reaction, is the predominant fatty acid of human adipose tissue triacylglycerols, associating SCD1 with the development of obesity and the metabolic syndrome. (Review) (PMID:20713121)
• We provide novel information that SCD1 activity and mRNA expression appear not to be elevated in subjects with high liver fat (PMID:21045174)
• Data suggest that the regulation of SCD1 is altered in individuals with morbid obesity and that the SCD1 protein has a different regulation in the two adipose tissues, as well as being closely linked to the degree of insulin resistance. (PMID:21060977)
• stearoyl-CoA desaturase 1 inhibition induces CHOP-dependent cell death in human cancer cells (PMID:21179554)
• stearoyl-CoA desaturase plays a key role in the regulation of androgen receptor transcriptional activity in prostate cancer cells (PMID:21331774)
• study showed cystic fibrosis cells exhibit increased metabolism along metabolic pathways leading to n-7 and n-9 fatty acids compared with wild-type cells; changes are accompanied by increased expression of Delta5, Delta6 and Delta9 desaturases and elongases 5 and 6 (PMID:21544602)
• Repression of SCD1 by alpha-linolenic acid favorably increased cholesterol efflux and decreased cholesterol accumulation in foam cells. (PMID:21658928)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	scdb	ENSDARG00000030265
danio_rerio	scd	ENSDARG00000033662
mus_musculus	Scd2	ENSMUSG00000025203
mus_musculus	Scd4	ENSMUSG00000050195
rattus_norvegicus	Scd2	ENSRNOG00000046005
caenorhabditis_elegans		WBGENE00001397
caenorhabditis_elegans		WBGENE00001398
caenorhabditis_elegans		WBGENE00001399

Paralogs (1): SCD5 (ENSG00000145284)

Protein

Protein identifiers

Stearoyl-CoA desaturase — O00767 (reviewed: O00767)

Alternative names: Acyl-CoA desaturase, Delta(9)-desaturase, Fatty acid desaturase

All UniProt accessions (1): O00767

UniProt curated annotations — full annotation on UniProt →

Function. Stearoyl-CoA desaturase that utilizes O(2) and electrons from reduced cytochrome b5 to introduce the first double bond into saturated fatty acyl-CoA substrates. Catalyzes the insertion of a cis double bond at the delta-9 position into fatty acyl-CoA substrates including palmitoyl-CoA and stearoyl-CoA. Gives rise to a mixture of 16:1 and 18:1 unsaturated fatty acids. Plays an important role in lipid biosynthesis. Plays an important role in regulating the expression of genes that are involved in lipogenesis and in regulating mitochondrial fatty acid oxidation. Plays an important role in body energy homeostasis. Contributes to the biosynthesis of membrane phospholipids, cholesterol esters and triglycerides.

Subunit / interactions. May self-associate and form homodimers.

Subcellular location. Endoplasmic reticulum membrane.

Tissue specificity. Detected in fetal liver, lung and brain. Highly expressed in adult adipose tissue, and at lower levels in adult brain and lung.

Cofactor. Expected to bind 2 Fe(2+) ions per subunit, instead of the Zn(2+) ions seen in the 3D-structure.

Domain organisation. The histidine box domains are involved in binding the catalytic metal ions.

Similarity. Belongs to the fatty acid desaturase type 1 family.

RefSeq proteins (1): NP_005054* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001522	FADS-1_CS	Conserved_site
IPR015876	Acyl-CoA_DS	Family

Enzyme classification (BRENDA):

• EC 1.14.19.1 — stearoyl-CoA 9-desaturase (BRENDA: 38 organisms, 111 substrates, 740 inhibitors, 12 Km, 4 kcat entries)

Substrate kinetics (BRENDA)

7 substrates with measured Km, best-characterized 7. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
STEAROYL-COA	0.0033–0.0566	4
NADH	0.003–0.089	2
NADPH	0.038–0.8	2
FAD	0.001	1
FMN	0.0025	1
N-HYDROXY-BENZENECARBOXIMIDAMIDE	—	0
STEAROYL-ACYL-CARRIER PROTEIN	—	0

Catalyzed reactions (Rhea), 2 shown:

• octadecanoyl-CoA + 2 Fe(II)-[cytochrome b5] + O2 + 2 H(+) = (9Z)-octadecenoyl-CoA + 2 Fe(III)-[cytochrome b5] + 2 H2O (RHEA:19721)
• hexadecanoyl-CoA + 2 Fe(II)-[cytochrome b5] + O2 + 2 H(+) = (9Z)-hexadecenoyl-CoA + 2 Fe(III)-[cytochrome b5] + 2 H2O (RHEA:36931)

UniProt features (71 total): helix 21, binding site 16, sequence conflict 9, topological domain 5, strand 5, transmembrane region 4, turn 4, short sequence motif 3, modified residue 2, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
4ZYO	X-RAY DIFFRACTION	3.25

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O00767-F1	90.01	0.85

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (16): 75; 120; 125; 148; 155; 156; 157; 160; 161; 188; 189; 262 …

Post-translational modifications (2): 198, 203

Function

Pathways and Gene Ontology

Reactome pathways

17 pathways

ID	Pathway
R-HSA-2426168	Activation of gene expression by SREBF (SREBP)
R-HSA-75105	Fatty acyl-CoA biosynthesis
R-HSA-9029558	NR1H2 & NR1H3 regulate gene expression linked to lipogenesis
R-HSA-9841922	MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
R-HSA-1430728	Metabolism
R-HSA-162582	Signal Transduction
R-HSA-1655829	Regulation of cholesterol biosynthesis by SREBP (SREBF)
R-HSA-212165	Epigenetic regulation of gene expression
R-HSA-556833	Metabolism of lipids
R-HSA-74160	Gene expression (Transcription)
R-HSA-8957322	Metabolism of steroids
R-HSA-8978868	Fatty acid metabolism
R-HSA-9006931	Signaling by Nuclear Receptors
R-HSA-9024446	NR1H2 and NR1H3-mediated signaling
R-HSA-9818564	Epigenetic regulation of gene expression by MLL3 and MLL4 complexes
R-HSA-9851695	Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes
R-HSA-9917777	Epigenetic regulation by WDR5-containing histone modifying complexes

MSigDB gene sets: 450 (showing top): FARMER_BREAST_CANCER_CLUSTER_7, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, MODULE_169, MODULE_255, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN, YAO_HOXA10_TARGETS_VIA_PROGESTERONE_UP, TTTGTAG_MIR520D, STEARMAN_LUNG_CANCER_EARLY_VS_LATE_DN, MENSE_HYPOXIA_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, MODULE_317, SHAFFER_IRF4_TARGETS_IN_ACTIVATED_B_LYMPHOCYTE, IVANOVA_HEMATOPOIESIS_MATURE_CELL, HUMMERICH_BENIGN_SKIN_TUMOR_DN

GO Biological Process (7): unsaturated fatty acid biosynthetic process (GO:0006636), response to fatty acid (GO:0070542), positive regulation of cold-induced thermogenesis (GO:0120162), monounsaturated fatty acid biosynthetic process (GO:1903966), lipid metabolic process (GO:0006629), fatty acid metabolic process (GO:0006631), fatty acid biosynthetic process (GO:0006633)

GO Molecular Function (7): stearoyl-CoA 9-desaturase activity (GO:0004768), iron ion binding (GO:0005506), oxidoreductase activity (GO:0016491), palmitoyl-CoA 9-desaturase activity (GO:0032896), protein binding (GO:0005515), oxidoreductase activity, acting on paired donors, with oxidation of a pair of donors resulting in the reduction of molecular oxygen to two molecules of water (GO:0016717), metal ion binding (GO:0046872)

GO Cellular Component (4): nucleolus (GO:0005730), endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-13 pathways:

Category	Pathways
Metabolism of lipids	2
Regulation of cholesterol biosynthesis by SREBP (SREBF)	1
Fatty acid metabolism	1
NR1H2 and NR1H3-mediated signaling	1
Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes	1
Metabolism of steroids	1
Gene expression (Transcription)	1
Metabolism	1
Signal Transduction	1
Signaling by Nuclear Receptors	1
Epigenetic regulation by WDR5-containing histone modifying complexes	1
Epigenetic regulation of gene expression by MLL3 and MLL4 complexes	1
Epigenetic regulation of gene expression	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
fatty acid biosynthetic process	2
acyl-CoA desaturase activity	2
unsaturated fatty acid metabolic process	1
response to lipid	1
response to oxygen-containing compound	1
positive regulation of multicellular organismal process	1
cold-induced thermogenesis	1
regulation of cold-induced thermogenesis	1
monounsaturated fatty acid metabolic process	1
primary metabolic process	1
lipid metabolic process	1
monocarboxylic acid metabolic process	1
fatty acid metabolic process	1
lipid biosynthetic process	1
monocarboxylic acid biosynthetic process	1
transition metal ion binding	1
catalytic activity	1
binding	1
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen	1
cation binding	1
nuclear lumen	1
intracellular membraneless organelle	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
cellular anatomical structure	1

Protein interactions and networks

STRING

2780 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SCD	CYB5B	O43169	984
SCD	CYB5A	P00167	979
SCD	FADS2	O95864	963
SCD	FADS1	O60427	948
SCD	FADS3	Q9Y5Q0	902
SCD	ACACA	Q13085	893
SCD	SREBF1	P36956	892
SCD	FASN	P49327	890
SCD	CYB5R4	Q7L1T6	868
SCD	DGAT2	Q96PD7	839
SCD	GPAM	Q9HCL2	828
SCD	CYB5RL	Q6IPT4	822
SCD	ELOVL6	Q9H5J4	820
SCD	CYB5R1	Q9UHQ9	818
SCD	CYB5R2	Q6BCY4	818

IntAct

181 interactions, top by confidence:

A	B	Type	Score
IFT70B	IFT56	psi-mi:“MI:0914”(association)	0.790
ESYT1	ESYT2	psi-mi:“MI:0914”(association)	0.770
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
SCD	TMPRSS2	psi-mi:“MI:0915”(physical association)	0.600
SCD	TIMMDC1	psi-mi:“MI:0915”(physical association)	0.560
SCD	HSD17B13	psi-mi:“MI:0915”(physical association)	0.560
SCD	SCN3B	psi-mi:“MI:0915”(physical association)	0.560
SCD	TMX2	psi-mi:“MI:0915”(physical association)	0.560
SCD	RETREG3	psi-mi:“MI:0915”(physical association)	0.560
SCD	RNF5	psi-mi:“MI:0915”(physical association)	0.560
SCD	SPAG4	psi-mi:“MI:0915”(physical association)	0.560
SCD	CLEC12B	psi-mi:“MI:0915”(physical association)	0.560
SCD	CD207	psi-mi:“MI:0915”(physical association)	0.560
SCD	REEP2	psi-mi:“MI:0915”(physical association)	0.560
SCD	CERS4	psi-mi:“MI:0915”(physical association)	0.560
SCD	SLC10A6	psi-mi:“MI:0915”(physical association)	0.560
SCD	GPX8	psi-mi:“MI:0915”(physical association)	0.560
SCD	CYB561	psi-mi:“MI:0915”(physical association)	0.560
SCD	SEC11C	psi-mi:“MI:0915”(physical association)	0.560
SCD	STOM	psi-mi:“MI:0915”(physical association)	0.560
SCD	TLCD4	psi-mi:“MI:0915”(physical association)	0.560
SCD	PVR	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (215): SCD (Affinity Capture-MS), HSD17B12 (Co-fractionation), NSUN5 (Co-fractionation), RPL14 (Co-fractionation), SCD (Co-fractionation), SCD (Co-fractionation), SCD (Co-fractionation), SCD (Co-fractionation), SSR4 (Co-fractionation), VAPB (Co-fractionation), VCP (Co-fractionation), SCD (Proximity Label-MS), SCD (Proximity Label-MS), SCD (Reconstituted Complex), SCD (Affinity Capture-MS)

ESM2 similar proteins: A0A0C5Q309, A3F5L2, A9SIZ6, B7SB91, B7SB92, C4R613, G5ED44, G5EG11, G5EGH6, G5EGN2, O00767, O02858, O04353, O44186, O44390, O59715, O62849, O74212, O94523, P07308, P13011, P13516, P48618, P48623, P48624, Q0VAX3, Q2KIA4, Q3EBF7, Q43469, Q594P3, Q59J82, Q64420, Q6P7B9, Q6RS96, Q6T707, Q6US81, Q704F0, Q75PL7, Q79EF1, Q86SK9

Diamond homologs: A0A0C5Q309, B7SB91, B7SB92, G5ED44, G5EGH6, G5EGN2, O00767, O02858, O44390, O62849, O94523, P07308, P0DOW2, P0DOW3, P13011, P13516, P21147, Q12618, Q2KIA4, Q64420, Q6P7B9, Q6T707, Q6US81, Q704E9, Q75PL7, Q79F73, Q86SK9, Q8ISS3, Q92038, Q95MI7, Q99PL7, Q9BH41, Q9FPD5, Q9LMI4, Q9LVZ3, Q9TT94, Q55406, Q949X0, Q9LMI3, Q9LND8

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
PRKAA1	“down-regulates quantity by repression”	SCD	“transcriptional regulation”
MK-8245	down-regulates	SCD	“chemical inhibition”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 112 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
PD-L1(CD274) glycosylation and translocation to plasma membrane	5	35.5×	4e-05
Regulation of CDH1 posttranslational processing and trafficking to plasma membrane	5	23.0×	2e-04
Maturation of spike protein	5	18.2×	5e-04
Maturation of DENV proteins	6	17.4×	1e-04
Regulation of RAS by GAPs	5	13.3×	1e-03
Asparagine N-linked glycosylation	7	5.8×	2e-03
Neutrophil degranulation	10	3.2×	8e-03

GO biological processes:

GO term	Partners	Fold	FDR
protein N-linked glycosylation	5	13.4×	8e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

33 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	20
Likely benign	2
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

993 predictions. Top by Δscore:

Variant	Effect	Δscore
10:100347526:G:GT	donor_gain	1.0000
10:100347529:GAT:G	donor_gain	1.0000
10:100347532:G:GG	donor_gain	1.0000
10:100348223:G:GT	donor_gain	1.0000
10:100352364:AGG:A	acceptor_gain	1.0000
10:100352365:GGG:G	acceptor_gain	1.0000
10:100354422:CCCA:C	acceptor_loss	1.0000
10:100354423:CCA:C	acceptor_loss	1.0000
10:100354424:CA:C	acceptor_loss	1.0000
10:100354425:A:AG	acceptor_gain	1.0000
10:100354425:AGAAT:A	acceptor_gain	1.0000
10:100354426:G:GC	acceptor_gain	1.0000
10:100354426:GA:G	acceptor_gain	1.0000
10:100354426:GAA:G	acceptor_gain	1.0000
10:100354426:GAAT:G	acceptor_gain	1.0000
10:100354426:GAATG:G	acceptor_gain	1.0000
10:100354575:G:T	donor_gain	1.0000
10:100354629:GGAG:G	donor_gain	1.0000
10:100354630:G:GT	donor_gain	1.0000
10:100354630:GAG:G	donor_gain	1.0000
10:100354632:GGTG:G	donor_loss	1.0000
10:100354633:G:GG	donor_gain	1.0000
10:100354634:T:G	donor_loss	1.0000
10:100360926:GTGGC:G	donor_gain	1.0000
10:100360927:TGGCT:T	donor_gain	1.0000
10:100360928:GGC:G	donor_gain	1.0000
10:100360928:GGCTG:G	donor_gain	1.0000
10:100360929:GC:G	donor_gain	1.0000
10:100360930:C:G	donor_gain	1.0000
10:100347477:A:T	donor_gain	0.9900

AlphaMissense

2363 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:100354442:T:A	W153R	0.999
10:100354442:T:C	W153R	0.999
10:100354444:G:C	W153C	0.999
10:100354444:G:T	W153C	0.999
10:100354454:C:G	H157D	0.999
10:100354458:G:C	R158P	0.999
10:100354466:C:G	H161D	0.999
10:100354535:T:A	W184R	0.999
10:100354535:T:C	W184R	0.999
10:100356679:C:A	N265K	0.999
10:100356679:C:G	N265K	0.999
10:100352413:C:G	H120D	0.998
10:100352422:T:A	W123R	0.998
10:100352422:T:C	W123R	0.998
10:100352428:C:G	H125D	0.998
10:100354449:G:C	R155P	0.998
10:100354456:C:A	H157Q	0.998
10:100354456:C:G	H157Q	0.998
10:100354457:C:A	R158S	0.998
10:100354463:C:G	H160D	0.998
10:100354496:C:G	H171D	0.998
10:100354520:T:C	F179L	0.998
10:100354522:C:A	F179L	0.998
10:100354522:C:G	F179L	0.998
10:100360745:C:G	H298D	0.998
10:100360750:C:A	N299K	0.998
10:100360750:C:G	N299K	0.998
10:100352416:C:A	R121S	0.997
10:100352425:A:C	S124R	0.997
10:100352427:C:A	S124R	0.997

dbSNP variants (sampled 300 via entrez): RS1000077946 (10:100358254 G>A), RS1000139666 (10:100358470 T>C), RS1000503829 (10:100346017 G>C), RS1000527886 (10:100345854 T>C,G), RS1000624603 (10:100359787 G>A), RS1000653929 (10:100350884 T>C), RS1000726671 (10:100350664 C>G,T), RS1000748531 (10:100346027 G>T), RS1001041543 (10:100352965 G>A), RS1001198692 (10:100359440 C>G), RS1001357616 (10:100351808 T>A), RS1001470244 (10:100351595 C>G,T), RS1001931503 (10:100349197 G>T), RS1002364518 (10:100346437 T>A,C), RS1002404261 (10:100348908 G>A,T)

Disease associations

OMIM: gene MIM:604031 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
adrenoleukodystrophy	Limited	Autosomal recessive

Mondo (1): adrenoleukodystrophy (MONDO:0018544)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D000326	Adrenoleukodystrophy	C10.228.140.163.100.084; C10.228.140.163.100.362.250; C10.228.140.695.625.250; C10.314.400.250; C10.597.606.360.455.124; C16.320.322.500.124; C16.320.400.525.124; C16.320.565.189.084; C16.320.565.189.362.250; C16.320.565.663.100; C18.452.132.100.084; C18.452.132.100.362.250; C18.452.648.189.084; C18.452.648.189.362.250; C18.452.648.663.100; C19.053.500.270

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5555 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 169 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1938870	MK-8245	1	169

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

148 measured of 182 human assays (182 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
2-[5-[3-[5-(trifluoromethoxy)spiro[3,4-dihydrochromene-2,4’-piperidine]-1’-yl]-1,2-oxazol-5-yl]tetrazol-2-yl]acetic acid	IC50	1 nM	US-9168248: Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
2-[5-[5-[5-(trifluoromethoxy)spiro[3,4-dihydrochromene-2,4’-piperidine]-1’-yl]-1,3,4-thiadiazol-2-yl]tetrazol-2-yl]acetic acid	IC50	1 nM	US-9168248: Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
2-[5-[2-[5-(trifluoromethoxy)spiro[3,4-dihydrochromene-2,4’-piperidine]-1’-yl]-1,3-thiazol-5-yl]tetrazol-2-yl]acetic acid	IC50	1 nM	US-9168248: Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
2-[5-[3-(5-bromospiro[3,4-dihydrochromene-2,4’-piperidine]-1’-yl)-1,2-oxazol-5-yl]tetrazol-2-yl]acetic acid	IC50	1 nM	US-9168248: Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
2-[5-[2-(5-bromospiro[3,4-dihydrochromene-2,4’-piperidine]-1’-yl)-1,3-thiazol-5-yl]tetrazol-2-yl]acetic acid	IC50	1 nM	US-9168248: Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
2-[5-[2-(5-methylspiro[3,4-dihydrochromene-2,4’-piperidine]-1’-yl)-1,3-thiazol-5-yl]tetrazol-2-yl]acetic acid	IC50	1 nM	US-9168248: Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
2-[5-[5-[5-(trifluoromethyl)spiro[3,4-dihydrochromene-2,4’-piperidine]-1’-yl]-1,3,4-thiadiazol-2-yl]tetrazol-2-yl]acetic acid	IC50	1 nM	US-9168248: Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
2-[5-[2-[5-(trifluoromethyl)spiro[3,4-dihydrochromene-2,4’-piperidine]-1’-yl]-1,3-thiazol-5-yl]tetrazol-2-yl]acetic acid	IC50	1 nM	US-9168248: Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
2-[3-[2-(5-chlorospiro[3,4-dihydrochromene-2,4’-piperidine]-1’-yl)-1,3-thiazol-5-yl]-2-oxoimidazol-1-yl]acetic acid	IC50	3 nM	US-9168248: Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
4-(2-chloro-5-fluorophenoxy)-N-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidine-1-carboxamide	IC50	10 nM	US-12268687: Compounds and uses thereof
2-[5-[3-(5-chlorospiro[3,4-dihydrochromene-2,4’-piperidine]-1’-yl)-1,2-oxazol-5-yl]tetrazol-2-yl]acetic acid	IC50	11 nM	US-9168248: Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
2-[5-[5-(5-chlorospiro[3,4-dihydrochromene-2,4’-piperidine]-1’-yl)-1,3,4-thiadiazol-2-yl]tetrazol-2-yl]acetic acid	IC50	12 nM	US-9168248: Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
2-[5-[2-(5-chloro-4-oxospiro[3H-chromene-2,4’-piperidine]-1’-yl)-1,3-thiazol-5-yl]tetrazol-2-yl]acetic acid	IC50	12 nM	US-9168248: Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
2-[5-[2-(5-chlorospiro[3,4-dihydrochromene-2,4’-piperidine]-1’-yl)-1,3-thiazol-5-yl]tetrazol-2-yl]acetic acid	IC50	13 nM	US-9168248: Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
2-[5-[5-(5-methoxyspiro[3,4-dihydrochromene-2,4’-piperidine]-1’-yl)-1,3,4-thiadiazol-2-yl]tetrazol-2-yl]acetic acid	IC50	13 nM	US-9168248: Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
2-[5-[3-(5-chloro-4-oxospiro[3H-chromene-2,4’-piperidine]-1’-yl)-1,2-oxazol-5-yl]tetrazol-2-yl]acetic acid	IC50	17 nM	US-9168248: Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
5-chloro-3-[4-(2-chloro-5-fluorophenoxy)piperidin-1-yl]-1-methylpyrazin-2-one	IC50	20 nM	US-8962837: Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics
N-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-(3-(trifluoromethyl)phenoxy)piperidine-1-carboxamide	IC50	20 nM	US-12268687: Compounds and uses thereof
2-[5-[2-(8-chloro-1-oxospiro[4H-isochromene-3,4’-piperidine]-1’-yl)-1,3-thiazol-5-yl]tetrazol-2-yl]acetic acid	IC50	21 nM	US-9168248: Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
2-[5-[5-(5-chloro-4-oxospiro[3H-chromene-2,4’-piperidine]-1’-yl)-1,3,4-thiadiazol-2-yl]tetrazol-2-yl]acetic acid	IC50	24 nM	US-9168248: Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
3-[4-(2-chloro-5-fluorophenoxy)piperidin-1-yl]-1,2,4-triazine	IC50	30 nM	US-8962837: Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics
1-(1,2,4-triazin-3-yl)-N-[2-(trifluoromethyl)phenyl]piperidin-4-amine	IC50	30 nM	US-8962837: Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics
4-(3,5-difluorophenoxy)-N-(1,5-dimethyl-6-oxopyridazin-3-yl)piperidine-1-carboxamide	IC50	40 nM	US-12268687: Compounds and uses thereof
2-[5-[2-(4-oxospiro[3H-chromene-2,4’-piperidine]-1’-yl)-1,3-thiazol-5-yl]tetrazol-2-yl]acetic acid	IC50	41 nM	US-9168248: Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
2-[5-(2-spiro[1,2-dihydroindene-3,4’-piperidine]-1’-yl-1,3-thiazol-5-yl)tetrazol-2-yl]acetic acid	IC50	49 nM	US-9168248: Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
4-(2-chloro-5-fluorophenoxy)-N-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidine-1-carboxamide	IC50	50 nM	US-12268687: Compounds and uses thereof
4-[(3,5-difluorophenyl)methyl]-N-(1,5-dimethyl-6-oxopyridazin-3-yl)piperidine-1-carboxamide	IC50	50 nM	US-12268687: Compounds and uses thereof
4-(2-chloro-3,5-difluorobenzyl)-N-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidine-1-carboxamide	IC50	50 nM	US-12268687: Compounds and uses thereof
3-[4-(2-bromo-4,5-difluorophenoxy)piperidin-1-yl]-1,2,4-triazine	IC50	55 nM	US-8962837: Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics
4-(2,3-dichlorophenoxy)-N-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidine-1-carboxamide	IC50	60 nM	US-12268687: Compounds and uses thereof
2-[5-[2-(5-chloro-4-oxospiro[3H-1,3-benzoxazine-2,4’-piperidine]-1’-yl)-1,3-thiazol-5-yl]tetrazol-2-yl]acetic acid	IC50	62 nM	US-9168248: Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
3-[4-(2-chloro-5-nitrophenoxy)piperidin-1-yl]-1,2,4-triazine	IC50	65 nM	US-8962837: Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics
2-[5-(2-spiro[2H-1-benzofuran-3,4’-piperidine]-1’-yl-1,3-thiazol-5-yl)tetrazol-2-yl]acetic acid	IC50	65 nM	US-9168248: Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
4-(3-fluoro-4-(trifluoromethyl)phenoxy)-N-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidine-1-carboxamide	IC50	70 nM	US-12268687: Compounds and uses thereof
4-[4-fluoro-2-(trifluoromethyl)phenoxy]-N-(1-methyl-6-oxopyridazin-3-yl)piperidine-1-carboxamide	IC50	80 nM	US-12268687: Compounds and uses thereof
4-(2-chloro-4,5-difluorobenzyl)-N-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidine-1-carboxamide	IC50	80 nM	US-12268687: Compounds and uses thereof
1-methyl-3-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]pyrazin-2-one	IC50	100 nM	US-8962837: Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics
3-[4-[2-chloro-5-(trifluoromethyl)phenoxy]piperidin-1-yl]-1,2,4-triazine	IC50	100 nM	US-8962837: Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics
3-[4-(2-chloro-5-fluorophenoxy)piperidin-1-yl]-5-methyl-1,2,4-triazine	IC50	100 nM	US-8962837: Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics
3-[4-(2-chloro-5-fluorophenoxy)piperidin-1-yl]-6-methyl-1,2,4-triazine	IC50	100 nM	US-8962837: Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics
4-(3-chloro-4,5-difluorobenzyl)-N-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidine-1-carboxamide	IC50	130 nM	US-12268687: Compounds and uses thereof
4-(3-chloro-5-fluorobenzyl)-N-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidine-1-carboxamide	IC50	160 nM	US-12268687: Compounds and uses thereof
4-(2-Chloro-3-fluorophenoxy)-N-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidine-1-carboxamide	IC50	170 nM	US-12268687: Compounds and uses thereof
6-(5-(4-(3,5-difluorobenzyl)piperidin-1-yl)-1,3,4-thiadiazol-2-yl)-2-methylpyridazin-3(2H)-one	IC50	180 nM	US-12268687: Compounds and uses thereof
2-[5-[2-(4-oxospiro[3H-1,3-benzoxazine-2,4’-piperidine]-1’-yl)-1,3-thiazol-5-yl]tetrazol-2-yl]acetic acid	IC50	181 nM	US-9168248: Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
5-chloro-1-methyl-3-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]pyrazin-2-one	IC50	200 nM	US-8962837: Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics
5-chloro-3-[4-[2-chloro-5-(trifluoromethyl)phenoxy]piperidin-1-yl]-1-methylpyrazin-2-one	IC50	200 nM	US-8962837: Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics
4-[4-[2-chloro-5-(trifluoromethyl)phenoxy]piperidin-1-yl]-2-methylpyridazin-3-one	IC50	200 nM	US-8962837: Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics
4-(3,4-difluorophenoxy)-N-(1,5-dimethyl-6-oxopyridazin-3-yl)piperidine-1-carboxamide	IC50	200 nM	US-12268687: Compounds and uses thereof
N-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-(2-(trifluoromethyl)phenoxy)piperidine-1-carboxamide	IC50	220 nM	US-12268687: Compounds and uses thereof

ChEMBL bioactivities

838 potent at pChembl≥5 of 911 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.52	IC50	0.03	nM	CHEMBL593108
10.40	IC50	0.04	nM	CHEMBL564507
10.30	IC50	0.05	nM	CHEMBL494748
10.22	IC50	0.06	nM	CHEMBL593108
10.22	IC50	0.06	nM	CHEMBL1276595
10.17	IC50	0.068	nM	CHEMBL594289
10.00	IC50	0.1	nM	CHEMBL1276623
9.70	IC50	0.2	nM	CHEMBL552173
9.70	IC50	0.2	nM	CHEMBL1276653
9.52	IC50	0.3	nM	CHEMBL552173
9.52	IC50	0.3	nM	CHEMBL1276654
9.35	IC50	0.45	nM	CHEMBL605412
9.32	IC50	0.48	nM	CHEMBL595247
9.30	IC50	0.5	nM	CHEMBL3127535
9.30	IC50	0.5	nM	CHEMBL572876
9.25	IC50	0.56	nM	CHEMBL594084
9.22	IC50	0.6	nM	CHEMBL549625
9.22	IC50	0.6	nM	CHEMBL557445
9.16	IC50	0.69	nM	CHEMBL607314
9.15	IC50	0.7	nM	CHEMBL1276653
9.15	IC50	0.7	nM	CHEMBL1276654
9.10	IC50	0.8	nM	CHEMBL593108
9.00	IC50	1	nM	MK-8245
9.00	IC50	1	nM	CHEMBL3970644
9.00	IC50	1	nM	CHEMBL3895997
9.00	IC50	1	nM	CHEMBL3914019
9.00	IC50	1	nM	CHEMBL3942017
9.00	IC50	1	nM	CHEMBL3919514
9.00	IC50	1	nM	CHEMBL3979824
9.00	IC50	1	nM	CHEMBL3976984
9.00	IC50	1	nM	CHEMBL3914136
9.00	IC50	1	nM	CHEMBL552126
9.00	IC50	1	nM	CHEMBL550800
9.00	IC50	1	nM	CHEMBL595254
9.00	IC50	1	nM	CHEMBL595255
9.00	IC50	1	nM	CHEMBL594071
9.00	IC50	1	nM	CHEMBL1087015
9.00	IC50	1	nM	CHEMBL1276685
9.00	IC50	1	nM	CHEMBL1276595
9.00	IC50	1	nM	CHEMBL1276623
8.92	IC50	1.2	nM	CHEMBL4066506
8.70	IC50	2	nM	CHEMBL3127534
8.70	IC50	2	nM	CHEMBL3127654
8.70	IC50	2	nM	CHEMBL549758
8.70	IC50	2	nM	CHEMBL552270
8.70	IC50	2	nM	CHEMBL594995
8.70	IC50	2	nM	CHEMBL595254
8.64	IC50	2.3	nM	CHEMBL4104190
8.60	IC50	2.5	nM	CHEMBL4094042
8.57	IC50	2.7	nM	CHEMBL575817

PubChem BioAssay actives

604 with measured affinity, of 861 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
1’-[6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl]-5-(trifluoromethyl)spiro[3,4-dihydrochromene-2,4’-piperidine]	535944: Inhibition of human SCD1	ic50	<0.0001	uM
4-(ethylamino)-3-(2-hydroxyethoxy)-N-[5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-2-yl]benzamide	426050: Inhibition of stearoyl-CoA desaturase 1 in human microsome assessed as conversion of [14C]stearate to [14C]oleate	ic50	<0.0001	uM
5-chloro-1’-[6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl]spiro[3,4-dihydrochromene-2,4’-piperidine]	535945: Inhibition of SCD1 in HEK293A cell microsomes assessed as reduction in conversion of [14C]stearic acid to [14C]oleic acid after 30 mins	ic50	0.0001	uM
N-[2-[7-[[4-chloro-3-(trifluoromethyl)phenyl]methylamino]-3-(4-methoxyphenyl)-2-oxoquinoxalin-1-yl]ethyl]acetamide	1859284: Inhibition of SCD in human HepG2 cells	ic50	0.0001	uM
N-(2-hydroxy-2-phenylethyl)-6-spiro[3,4-dihydrochromene-2,4’-piperidine]-1’-ylpyridazine-3-carboxamide	455002: Inhibition of human SCD1 expressed in human 293A cells assessed as conversion of [14C]stearate to [14C]oleate	ic50	0.0001	uM
5,8-difluoro-1’-[6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl]spiro[3,4-dihydrochromene-2,4’-piperidine]	535945: Inhibition of SCD1 in HEK293A cell microsomes assessed as reduction in conversion of [14C]stearic acid to [14C]oleic acid after 30 mins	ic50	0.0001	uM
N-[5-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1,3-thiazol-2-yl]-3-(2-hydroxyethoxy)-4-methoxybenzamide	430729: Inhibition of SCD1 in human microsomes assessed as conversion of [14C]stearate to [14C]oleate after 60 mins	ic50	0.0002	uM
5-methyl-1’-[6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl]spiro[3,4-dihydrochromene-2,4’-piperidine]	535945: Inhibition of SCD1 in HEK293A cell microsomes assessed as reduction in conversion of [14C]stearic acid to [14C]oleic acid after 30 mins	ic50	0.0002	uM
5-fluoro-1’-[6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl]spiro[3,4-dihydrochromene-2,4’-piperidine]	535945: Inhibition of SCD1 in HEK293A cell microsomes assessed as reduction in conversion of [14C]stearic acid to [14C]oleic acid after 30 mins	ic50	0.0003	uM
N-(2-hydroxy-2-pyridin-3-ylethyl)-6-[5-(trifluoromethyl)spiro[3,4-dihydrochromene-2,4’-piperidine]-1’-yl]pyridazine-3-carboxamide	455000: Inhibition of SCD1 in human 293A cells assessed as conversion of [14C]stearate to [14C]oleate after 60 mins in presence of S9 microsomal fraction	ic50	0.0004	uM
N-[2-[6-[(3,4-dichlorophenyl)methylamino]-3-oxo-1,4-benzoxazin-4-yl]ethyl]-2-hydroxyacetamide	436928: Inhibition of stearoyl-CoA delta9 desaturase in human HepG2 cells	ic50	0.0005	uM
N-(2-hydroxy-2-phenylethyl)-6-(4-hydroxyspiro[3,4-dihydrochromene-2,4’-piperidine]-1’-yl)pyridazine-3-carboxamide	455002: Inhibition of human SCD1 expressed in human 293A cells assessed as conversion of [14C]stearate to [14C]oleate	ic50	0.0005	uM
[5-[6-[4-(6-fluoro-2,3-dihydroindol-1-yl)piperidin-1-yl]pyridazin-3-yl]-2-pyridinyl]methanol	1074265: Inhibition of SCD1 in human A431 cells assessed as [13C]-palmitic acid conversion to [13C]-palmitoleic acid after 4 hrs by LC/MS analysis	ic50	0.0005	uM
3-(2-hydroxyethoxy)-4-(2-methoxyethoxy)-N-[5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-2-yl]benzamide	426050: Inhibition of stearoyl-CoA desaturase 1 in human microsome assessed as conversion of [14C]stearate to [14C]oleate	ic50	0.0006	uM
N-[5-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-2-yl]-3-(2-hydroxyethoxy)-4-methoxybenzamide	430729: Inhibition of SCD1 in human microsomes assessed as conversion of [14C]stearate to [14C]oleate after 60 mins	ic50	0.0006	uM
N-(2-hydroxy-2-phenylethyl)-6-(3-hydroxyspiro[3,4-dihydrochromene-2,4’-piperidine]-1’-yl)pyridazine-3-carboxamide	455002: Inhibition of human SCD1 expressed in human 293A cells assessed as conversion of [14C]stearate to [14C]oleate	ic50	0.0006	uM
N-(2-hydroxy-2-phenylethyl)-6-(4-oxospiro[3H-chromene-2,4’-piperidine]-1’-yl)pyridazine-3-carboxamide	455002: Inhibition of human SCD1 expressed in human 293A cells assessed as conversion of [14C]stearate to [14C]oleate	ic50	0.0007	uM
[3-[2-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]-1,3-thiazol-5-yl]-1,2,4-oxadiazol-5-yl]methanol	464562: Inhibition of SCD1 in human HepG2 cells assessed as [14C]stearic acid to [14C]oleic acid conversion pretreated 15 mins before [14C]stearic acid addition measured after 4 hrs by HPLC based scintillation assay	ic50	0.0010	uM
2-[5-[3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,2-oxazol-5-yl]tetrazol-2-yl]acetic acid	692201: Inhibition of human SCD-1	ic50	0.0010	uM
1’-[6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl]spiro[3,4-dihydrochromene-2,4’-piperidine]	535945: Inhibition of SCD1 in HEK293A cell microsomes assessed as reduction in conversion of [14C]stearic acid to [14C]oleic acid after 30 mins	ic50	0.0010	uM
6-(5-chlorospiro[3,4-dihydrochromene-2,4’-piperidine]-1’-yl)-N-(2-hydroxy-2-pyridin-3-ylethyl)pyridazine-3-carboxamide	455000: Inhibition of SCD1 in human 293A cells assessed as conversion of [14C]stearate to [14C]oleate after 60 mins in presence of S9 microsomal fraction	ic50	0.0010	uM
N-[5-[(3,4-dichlorophenyl)methyl]-1,3-thiazol-2-yl]-3-(2-hydroxyethoxy)-4-methoxybenzamide	430729: Inhibition of SCD1 in human microsomes assessed as conversion of [14C]stearate to [14C]oleate after 60 mins	ic50	0.0010	uM
N-[5-[(3,5-dichlorophenyl)methyl]-1,3-thiazol-2-yl]-3-(2-hydroxyethoxy)-4-methoxybenzamide	430729: Inhibition of SCD1 in human microsomes assessed as conversion of [14C]stearate to [14C]oleate after 60 mins	ic50	0.0010	uM
N-(2-hydroxy-2-pyridin-3-ylethyl)-6-(5-methylspiro[3,4-dihydrochromene-2,4’-piperidine]-1’-yl)pyridazine-3-carboxamide	455000: Inhibition of SCD1 in human 293A cells assessed as conversion of [14C]stearate to [14C]oleate after 60 mins in presence of S9 microsomal fraction	ic50	0.0010	uM
1’-[6-[5-(pyridin-3-ylmethyl)-1H-1,2,4-triazol-3-yl]pyridazin-3-yl]-5-(trifluoromethyl)spiro[3,4-dihydrochromene-2,4’-piperidine]	455000: Inhibition of SCD1 in human 293A cells assessed as conversion of [14C]stearate to [14C]oleate after 60 mins in presence of S9 microsomal fraction	ic50	0.0010	uM
[5-[6-[4-(trifluoromethyl)-4-[4-(trifluoromethyl)phenyl]piperidin-1-yl]pyridazin-3-yl]-1,2,4-thiadiazol-3-yl]methanol	1485983: Displacement of (5-(6-(10H-spiro(1-benzofuran-3,30-pyrrolidin)-10-yl)pyridazin-3-yl)-1,2,4-oxadiazol-3-yl)[3H2]methanol from SCD1 in human liver microsomes after 120 mins TopCount liquid scintillation counting method	ic50	0.0012	uM
N-[5-[(3-chloro-4-fluorophenyl)methyl]-1,3-thiazol-2-yl]-3-(2-hydroxyethoxy)-4-methoxybenzamide	430729: Inhibition of SCD1 in human microsomes assessed as conversion of [14C]stearate to [14C]oleate after 60 mins	ic50	0.0020	uM
4-ethoxy-3-(2-hydroxyethoxy)-N-[5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-2-yl]benzamide	426050: Inhibition of stearoyl-CoA desaturase 1 in human microsome assessed as conversion of [14C]stearate to [14C]oleate	ic50	0.0020	uM
6-(5,8-difluorospiro[3,4-dihydrochromene-2,4’-piperidine]-1’-yl)-N-(2-hydroxy-2-pyridin-3-ylethyl)pyridazine-3-carboxamide	455000: Inhibition of SCD1 in human 293A cells assessed as conversion of [14C]stearate to [14C]oleate after 60 mins in presence of S9 microsomal fraction	ic50	0.0020	uM
6-fluoro-1-[1-[6-(6-methyl-3-pyridinyl)pyridazin-3-yl]piperidin-4-yl]-2,3-dihydroindole	1074265: Inhibition of SCD1 in human A431 cells assessed as [13C]-palmitic acid conversion to [13C]-palmitoleic acid after 4 hrs by LC/MS analysis	ic50	0.0020	uM
2-[6-[4-(6-fluoro-2,3-dihydroindol-1-yl)piperidin-1-yl]pyridazin-3-yl]-4-methyl-1,3-thiazole	1074265: Inhibition of SCD1 in human A431 cells assessed as [13C]-palmitic acid conversion to [13C]-palmitoleic acid after 4 hrs by LC/MS analysis	ic50	0.0020	uM
[5-[6-[4-(trifluoromethyl)-4-[4-(trifluoromethyl)phenyl]piperidin-1-yl]pyridazin-3-yl]-1,2,4-oxadiazol-3-yl]methanol	1485983: Displacement of (5-(6-(10H-spiro(1-benzofuran-3,30-pyrrolidin)-10-yl)pyridazin-3-yl)-1,2,4-oxadiazol-3-yl)[3H2]methanol from SCD1 in human liver microsomes after 120 mins TopCount liquid scintillation counting method	ic50	0.0023	uM
[5-[6-[4-(trifluoromethyl)-4-[4-(trifluoromethyl)phenyl]piperidin-1-yl]pyridazin-3-yl]-1,3,4-thiadiazol-2-yl]methanol	1485983: Displacement of (5-(6-(10H-spiro(1-benzofuran-3,30-pyrrolidin)-10-yl)pyridazin-3-yl)-1,2,4-oxadiazol-3-yl)[3H2]methanol from SCD1 in human liver microsomes after 120 mins TopCount liquid scintillation counting method	ic50	0.0025	uM
2-hydroxy-N-[2-[2-oxo-3-(trifluoromethyl)-7-[[3-(trifluoromethyl)phenyl]methylamino]quinoxalin-1-yl]ethyl]acetamide	436928: Inhibition of stearoyl-CoA delta9 desaturase in human HepG2 cells	ic50	0.0027	uM
N-[5-(hydroxymethyl)-1,3-thiazol-2-yl]-4-[[2-(trifluoromethyl)anilino]methyl]benzamide	1421978: Inhibition of recombinant human SCD1 expressed in baculovirus expression system assessed as reduction in [3H]H2O production using stearoyl [9,10-3H]CoA as substrate in presence of NADH incubated for 30 mins by scintillation counting method	ic50	0.0028	uM
3-[2-(4-methoxyphenyl)-3-oxo-6-[[3-(trifluoromethyl)phenyl]methylamino]pyrido[2,3-b]pyrazin-4-yl]propanamide	414423: Inhibition of Delta-9-desaturase in human HepG2 cells	ic50	0.0028	uM
N-[5-[(3,5-difluorophenyl)methyl]-1,3-thiazol-2-yl]-3-(2-hydroxyethoxy)-4-methoxybenzamide	430729: Inhibition of SCD1 in human microsomes assessed as conversion of [14C]stearate to [14C]oleate after 60 mins	ic50	0.0029	uM
(E)-3-(4-methoxyphenyl)-N-[5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-2-yl]prop-2-enamide	430729: Inhibition of SCD1 in human microsomes assessed as conversion of [14C]stearate to [14C]oleate after 60 mins	ic50	0.0030	uM
4-[(2-butylanilino)methyl]-N-[4-(2-hydroxyethyl)-1,3-thiazol-2-yl]benzamide	1421978: Inhibition of recombinant human SCD1 expressed in baculovirus expression system assessed as reduction in [3H]H2O production using stearoyl [9,10-3H]CoA as substrate in presence of NADH incubated for 30 mins by scintillation counting method	ic50	0.0030	uM
2-[2-[[4-[(2-hexylanilino)methyl]benzoyl]amino]-1,3-thiazol-4-yl]acetic acid	1421978: Inhibition of recombinant human SCD1 expressed in baculovirus expression system assessed as reduction in [3H]H2O production using stearoyl [9,10-3H]CoA as substrate in presence of NADH incubated for 30 mins by scintillation counting method	ic50	0.0030	uM
N-(4-chlorophenyl)-6-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyridazine-3-carboxamide	721942: Inhibition of SCD1 in human HepG2 cells using [14C]-stearate substrate assessed as decreased production of [14C]-oleic acid after 24 hrs	ic50	0.0030	uM
3-(2-hydroxyethoxy)-4-methoxy-N-[5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-2-yl]benzamide	426050: Inhibition of stearoyl-CoA desaturase 1 in human microsome assessed as conversion of [14C]stearate to [14C]oleate	ic50	0.0030	uM
[1-[6-[4-(6-fluoro-2,3-dihydroindol-1-yl)piperidin-1-yl]pyridazin-3-yl]imidazol-4-yl]methanol	1074265: Inhibition of SCD1 in human A431 cells assessed as [13C]-palmitic acid conversion to [13C]-palmitoleic acid after 4 hrs by LC/MS analysis	ic50	0.0030	uM
N-[2-[7-[(4-fluoro-3-methylphenyl)methylamino]-3-(4-methoxyphenyl)-2-oxoquinoxalin-1-yl]ethyl]acetamide	414423: Inhibition of Delta-9-desaturase in human HepG2 cells	ic50	0.0031	uM
N-[2-[3-(4-ethylphenyl)-2-oxo-7-[[3-(trifluoromethyl)phenyl]methylamino]quinoxalin-1-yl]ethyl]acetamide	414423: Inhibition of Delta-9-desaturase in human HepG2 cells	ic50	0.0032	uM
4-[(2-butylanilino)methyl]-N-[4-(hydroxymethyl)-1,3-thiazol-2-yl]benzamide	1421978: Inhibition of recombinant human SCD1 expressed in baculovirus expression system assessed as reduction in [3H]H2O production using stearoyl [9,10-3H]CoA as substrate in presence of NADH incubated for 30 mins by scintillation counting method	ic50	0.0032	uM
N-[2-[3-(4-methoxyphenyl)-2-oxo-7-[[3-(trifluoromethyl)phenyl]methylamino]quinoxalin-1-yl]ethyl]acetamide	414423: Inhibition of Delta-9-desaturase in human HepG2 cells	ic50	0.0033	uM
N-[4-(hydroxymethyl)-1,3-thiazol-2-yl]-4-[[2-(trifluoromethyl)anilino]methyl]benzamide	1421978: Inhibition of recombinant human SCD1 expressed in baculovirus expression system assessed as reduction in [3H]H2O production using stearoyl [9,10-3H]CoA as substrate in presence of NADH incubated for 30 mins by scintillation counting method	ic50	0.0038	uM
N-[5-(2-hydroxyethyl)-1,3-thiazol-2-yl]-4-[[2-(trifluoromethyl)anilino]methyl]benzamide	1421978: Inhibition of recombinant human SCD1 expressed in baculovirus expression system assessed as reduction in [3H]H2O production using stearoyl [9,10-3H]CoA as substrate in presence of NADH incubated for 30 mins by scintillation counting method	ic50	0.0038	uM
N-[4-(2-hydroxyethyl)-1,3-thiazol-2-yl]-5-[[2-(trifluoromethyl)anilino]methyl]thiophene-2-carboxamide	1421978: Inhibition of recombinant human SCD1 expressed in baculovirus expression system assessed as reduction in [3H]H2O production using stearoyl [9,10-3H]CoA as substrate in presence of NADH incubated for 30 mins by scintillation counting method	ic50	0.0039	uM

CTD chemical–gene interactions

246 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
fatostatin	decreases expression, increases response to substance, affects reaction, increases reaction	8
Benzo(a)pyrene	decreases expression, increases methylation, affects cotreatment, affects expression	8
T0901317	affects cotreatment, increases expression, decreases reaction	7
Valproic Acid	affects reaction, increases expression, affects expression, decreases expression	7
Oleic Acid	affects cotreatment, decreases expression, decreases reaction, increases expression, affects expression (+1 more)	7
bisphenol A	affects expression, increases expression	6
Rosiglitazone	increases expression, affects cotreatment, affects expression, affects reaction, increases activity	6
perfluorooctanoic acid	affects cotreatment, decreases expression, increases expression	5
Tretinoin	decreases expression, increases expression	5
Aflatoxin B1	decreases expression, decreases methylation, affects expression, affects cotreatment	5
Palmitic Acid	increases expression, affects cotreatment, affects expression, affects reaction, decreases reaction	5
sodium arsenite	decreases expression, increases abundance, increases expression, affects cotreatment	4
cobaltous chloride	decreases expression, increases expression, decreases reaction	4
Amiodarone	decreases reaction, increases expression, affects reaction, increases uptake, decreases activity	4
Cyclosporine	affects cotreatment, decreases expression	4
Genistein	decreases expression, increases expression	4
mono-(2-ethylhexyl)phthalate	affects expression, increases expression	3
perfluorobutyric acid	affects cotreatment, decreases expression, increases expression	3
cylindrospermopsin	decreases expression	3
Fluorouracil	decreases expression, increases expression, affects response to substance, decreases reaction	3
Tetrachlorodibenzodioxin	decreases expression, increases expression	3
Particulate Matter	increases abundance, increases expression, affects cotreatment, decreases expression	3
betulin	decreases expression	2
benzo(b)fluoranthene	affects cotreatment, decreases expression, affects expression	2
ochratoxin A	decreases expression	2
potassium chromate(VI)	affects cotreatment, increases expression	2
cupric chloride	decreases expression	2
perfluorodecanoic acid	affects reaction, increases expression, affects cotreatment	2
perfluoro-n-heptanoic acid	increases expression	2
GW 7647	affects cotreatment, decreases expression, increases expression	2

ChEMBL screening assays

83 unique, capped per target: 74 binding, 8 admet, 1 unclassified

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1010955	Binding	Inhibition of Delta-9-desaturase in human HepG2 cells	Novel, potent, selective, and metabolically stable stearoyl-CoA desaturase (SCD) inhibitors. — Bioorg Med Chem Lett
CHEMBL4626519	ADMET	Inhibition of SCD in human H2009 cells non-expressing CYP4F11 assessed as reduction in cell viability incubated for 96 hrs by cell titer Glo reagent based assay	Tumor-Activated Benzothiazole Inhibitors of Stearoyl-CoA Desaturase. — J Med Chem
CHEMBL4626521	Unclassified	Selectivity index, ratio of IC50 for inhibition of SCD in human H2009 cells non-expressing CYP4F11 to IC50 for inhibition of SCD in human NCI-H2122 cells expressing CYP4F11	Tumor-Activated Benzothiazole Inhibitors of Stearoyl-CoA Desaturase. — J Med Chem

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2EP	Abcam HeLa SCD KO	Cancer cell line	Female

Clinical trials (associated diseases)

48 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05003648	PHASE4	ACTIVE_NOT_RECRUITING	Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy
NCT00007020	PHASE3	COMPLETED	Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid
NCT00545597	PHASE3	TERMINATED	A Phase III Trial of Lorenzo’s Oil in Adrenomyeloneuropathy
NCT00004418	PHASE2	TERMINATED	Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy
NCT00383448	PHASE2	COMPLETED	HSCT for High Risk Inherited Inborn Errors
NCT01043640	PHASE2	COMPLETED	Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
NCT03864523	PHASE2	COMPLETED	Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy
NCT05200104	PHASE2	WITHDRAWN	Study to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)
NCT01586455	PHASE1	COMPLETED	Human Placental-Derived Stem Cell Transplantation
NCT01787578	PHASE1	WITHDRAWN	Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD)
NCT02254863	PHASE1	RECRUITING	UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
NCT02595489	PHASE1	COMPLETED	A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy
NCT00176904	PHASE2/PHASE3	COMPLETED	Stem Cell Transplant for Inborn Errors of Metabolism
NCT02961803	PHASE2/PHASE3	COMPLETED	MD1003-AMN MD1003 in Adrenomyeloneuropathy
NCT03231878	PHASE2/PHASE3	COMPLETED	A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.
NCT04303416	PHASE2/PHASE3	COMPLETED	Plasma Exchange With Albumin in AMN Patients
NCT01372228	PHASE1/PHASE2	TERMINATED	Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders
NCT02559830	PHASE1/PHASE2	UNKNOWN	Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy
NCT03196765	PHASE1/PHASE2	WITHDRAWN	Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy
NCT03513328	PHASE1/PHASE2	COMPLETED	Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
NCT05394064	PHASE1/PHASE2	TERMINATED	A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)
NCT00004442	Not specified	TERMINATED	Study of Bile Acids in Patients With Peroxisomal Disorders
NCT00004450	Not specified	COMPLETED	Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy
NCT00005900	Not specified	UNKNOWN	Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
NCT00278044	Not specified	UNKNOWN	Clinical Study and Gene Mutation Analysis of Adrenoleukodystrophy in Taiwanese Children
NCT01165060	Not specified	COMPLETED	The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD)
NCT01594853	Not specified	COMPLETED	Exercise Study of Function and Pathology for Women With X-linked Adrenoleukodystrophy
NCT02204904	Not specified	TERMINATED	Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)
NCT02233257	Not specified	NO_LONGER_AVAILABLE	Expanded Access for Lorenzo’s Oil (GTO/GTE) in Adrenoleukodystrophy
NCT02698579	Not specified	ACTIVE_NOT_RECRUITING	Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product
NCT02699190	Not specified	COMPLETED	LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
NCT02948062	Not specified	WITHDRAWN	Early Diagnosis Of Childhood Cerebral ALD
NCT02952482	Not specified	COMPLETED	Newborn Screening for Adrenoleukodystrophy
NCT03047369	Not specified	RECRUITING	The Myelin Disorders Biorepository Project
NCT03278899	Not specified	UNKNOWN	A Study to Prospectively Assess Disease Progression in Male Children With X-ALD
NCT03333200	Not specified	RECRUITING	Longitudinal Study of Neurodegenerative Disorders
NCT03649919	Not specified	WITHDRAWN	Multi-center Clinical Study on the Diagnosis and Treatment Management of Rare Neurological Disease in Children
NCT03727555	Not specified	RECRUITING	IT and IV Lentiviral Gene Therapy for X-ALD
NCT03789721	Not specified	RECRUITING	Adrenoleukodystrophy National Registry Study
NCT04090268	Not specified	UNKNOWN	Precision Exercise in Children With Malignant Hemopathies